2025年上半年，华厦眼科积极引进国际前沿诊疗新技术、新设备，不断丰富公司在屈光手术、白内障手术及眼病诊疗领域的创新、个性化诊疗方案，持续引领眼科技术革新，推动公司诊疗设备 2025年5月，华厦眼科迎来了屈光手术领域的重大突破。公司下属的厦门眼科中心、郑州华厦视光、成都爱迪等多家医院，率先引进全球首款 2MHz 全飞秒激光设备 —— 蔡司新一代机器人全飞 白内障手术领域，公司率先引入全国首台强生第七代 "Catalys 白力士 7.0" 导航飞秒激光白内障手术系统，在手术精准度、安全性、手术时间和视觉质量上实现了革命性的突破，让白内障 在眼病诊疗方面，公司率先引进国际领先的强脉冲光干眼治疗仪 "OptiLight 点睛之笔"，为干眼患者带来了精准诊疗的新希望。同时，公司还引入了我国首台通过创新医疗器械特别审批的高 眼科医疗服务市场持续扩容，头部企业有望充分受益 近年来，在国家战略及政策的引导下，我国眼科医疗服务体系逐步完善，医疗服务能力持续提升，国民眼健康意识不断增强，推动眼科医疗服务需求持续增长，为眼科医疗行业企业特别是非公医 根据《2024 中国卫生健康统计年鉴》数据统计，2023 年，我国眼科门急诊人次 ...

8月24日下午，华厦眼科(301267)披露半年度报告。2025年上半年，公司交出了一份稳健增长的业绩答 卷，实现营业收入21.39亿元，同比增长4.31%；归母净利润达2.82亿元，同比增长6.20%。经历阶段性 挑战后，上半年公司营收利润重回上升轨道，经营韧性凸显。 上半年，受益于公司在眼科技术领域的持续创新和高端设备引进，屈光业务成为经营核心亮点之一，单 项业务收入同比增长13.75%，达到7.89亿元。同时，人才队伍作为服务质量的关键支撑，公司以"医教 研"协同发展结合激励机制优化，确保了诊疗服务的高水准，也为业绩回升奠定了坚实基础。 创新驱动发展，引领眼科技术革新 2025年以来，华厦眼科在技术创新领域持续发力，屈光和白内障业务成为重点突破方向。中报强调，报 告期内公司积极引进国际前沿诊疗新技术、新设备，不断丰富公司在屈光手术、白内障手术及眼病诊疗 领域的创新、个性化诊疗方案。 值得一提的是，除手术相关设备与技术外，报告期内公司持续深化AI、大数据等先进技术在眼科临床 诊疗中的应用，进一步加快数智化赋能。具体而言，在对外合作方面，上半年公司与厦门大学眼科研究 所联合发布国内首个干眼AI自测工具，以A ...

| 华厦眼科医院集团股份有限公司 | | 2025 年半年度报告全文 | | --- | --- | --- | | 华厦眼科医院集团股份有限公司 | | | | 华厦眼科医院集团股份有限公司 2025 年半年度报告全文 | | | | 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 | | | | 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 | | | | 个别和连带的法律责任。 | | | | 公司负责人苏庆灿、主管会计工作负责人陈凤国及会计机构负责人(会计 | | | | 主管人员)陈鹭燕声明：保证本半年度报告中财务报告的真实、准确、完整。 | | | | 除下列董事外，其他董事亲自出席了审议本次半年报的董事会会议： | | | | 未亲自出席董事姓名 未亲自出席董事职务 未亲自出席会议原因 被委托人姓名 | | | | 苏庆灿 董事长 因个人原因 陈凤国 | | | | 本报告涉及未来发展规划和经营计划等前瞻性描述不构成公司对投资者的 | | | | 实质承诺，投资者及相关人士均应当对此保持足够的风险认识，并且应当理 | | | | 解规划、计划、预测与承诺之间 ...

Group 1: Company Development Strategy - The company focuses on deepening existing markets and expanding new ones through the "1+8+N" model, enhancing core hospitals' leading roles to integrate regional medical resources [1] - Organizational changes are initiated to boost efficiency and talent development, aiming for high-quality growth in the next decade [1] - Emphasis on patient-centered care by optimizing processes to improve patient experience and satisfaction [1] Group 2: Expansion of Services - The company aims to establish a "star-and-moon" structure in regional markets, integrating hospitals and outpatient departments for better service delivery [2] - New services are developed to address changing eye health needs, including elderly eye disease diagnosis and treatment, in response to an aging population [2] - Transitioning from "single service" to "lifecycle service" to provide comprehensive eye health management [2] Group 3: International Business Growth - International operations are seen as a key growth area, with strategies focusing on careful expansion and local operations [3] - In Europe, a combination of acquisitions and new establishments has led to significant growth, with further potential for expansion [3] - The company retains local brands and management teams in overseas markets to ensure smooth integration and cultural alignment [4] Group 4: Technological Advancements - Continuous investment in eye care technology is crucial, with advancements in diagnostic and treatment methods driving industry progress [5] - The company covers a wide range of services, including refractive surgery and cataract treatment, forming a comprehensive eye care system [5] - Focus on integrating AI and digital health solutions to enhance service delivery and clinical research [5] Group 5: Response to Policy Changes and Competition - The company recognizes the impact of aging populations on healthcare funding and aims to expand its patient base through improved management and service quality [6] - Emphasis on developing non-insured services to create a differentiated competitive advantage [6] - The domestic market remains competitive, with the company leveraging its technological and service strengths to increase market share [6] Group 6: Talent Development and Incentives - A multi-layered incentive system is established to motivate staff and align their interests with the institution's performance [7] - Collaboration with educational institutions to cultivate high-level professionals and enhance existing team capabilities [7] - Focus on integrating clinical practice, education, and research to foster talent growth [7] Group 7: Strategies Against Industry Challenges - The company advocates for healthy competition in the medical field, emphasizing patient safety over cost-cutting [9] - Cost reduction strategies include process optimization and digital tools, while maintaining service quality [9] - Continuous technological innovation is essential to avoid price wars and enhance patient satisfaction [9]

Core Viewpoint - The ophthalmology industry has experienced a price war in refractive surgery over the past couple of years, but the situation is expected to improve starting from Q3 2024 due to brand reputation and advancements in surgical techniques [1] Company Summary - Aier Eye Hospital (300015) indicated that the average transaction price for refractive surgeries is stabilizing and expected to rise continuously from Q3 2024 onwards, benefiting from its brand reputation and the iterative upgrade of surgical methods [1]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1][6] Core Views - The company's performance is under short-term pressure, but the consumer ophthalmology sector shows steady growth [1][6] - The company is a large ophthalmology medical chain group integrating medical education and research, achieving stable growth through "internal growth + external mergers" [6] Financial Performance Summary - In 2024, the company achieved total revenue of 4,027 million yuan, a year-on-year increase of 0.35%, and a net profit attributable to the parent company of 428.64 million yuan, a year-on-year decrease of 35.63% [6][7] - For Q1 2025, the company reported revenue of 1,093 million yuan, a year-on-year increase of 11.74% and a quarter-on-quarter increase of 29.34%, with a net profit of 150 million yuan, a year-on-year decrease of 4.00% [6][7] - The company's gross profit margin for 2024 was 44.19%, and for Q1 2025, it was 44.97%, showing a decline compared to the previous year [6][7] Business Segment Performance - The cataract project generated revenue of 873 million yuan in 2024, a year-on-year decrease of 11.56%, while the refractive project achieved revenue of 1,296 million yuan, a year-on-year increase of 7.44% [6][7] - The company expects improvements in the refractive surgery business's unit price and gross margin due to the promotion of new technologies [6] Employee Incentives - The company announced an employee stock ownership plan to motivate core personnel, with a total of 752.78 million shares available for purchase at a price of 9.26 yuan per share [6] Profit Forecasts - The revised profit forecasts for 2025-2027 are net profits of 5.15 billion yuan, 6.05 billion yuan, and 6.97 billion yuan, respectively [6][7]

Group 1 - Refractive surgery is a surgical procedure that corrects vision by altering the eye's refractive system, primarily targeting myopia, hyperopia, and astigmatism [3] - The refractive surgery market is experiencing a new wave of transformation driven by advanced technologies such as precise femtosecond laser 4.0, all-light sculpting, and EVO+ICL, which are expected to significantly increase the average transaction price [1][2] - The domestic refractive surgery market was nearly 35 billion yuan in 2022, with a low penetration rate of 0.7 surgeries per thousand people in 2021, indicating substantial room for growth compared to developed countries like the US, which had 2.6 surgeries per thousand people [1][30] Group 2 - The refractive surgery sector is a core business in private ophthalmology, contributing significantly to profit growth due to its large market size and strong profitability [1][41] - The introduction of new technologies and equipment is anticipated to stimulate demand, leading to a potential price increase in refractive surgeries, alongside a recovery in consumer expectations [1][41] - Companies such as Aier Eye Hospital, Huaxia Eye Hospital, and others are recommended for attention due to their positioning in the growing refractive surgery market [1][41] Group 3 - The evolution of refractive surgery equipment has been steady, with significant advancements occurring approximately every decade, culminating in the upcoming launch of the VISUMAX 800 and SMILE pro in 2025 [8][12] - The new femtosecond laser 4.0 technology offers enhanced precision and customization, with a higher average transaction price compared to previous versions [9][10] - The all-light sculpting technique utilizes a 3D model of the eye and AI algorithms for personalized treatment, marking a significant advancement in refractive surgery [14] Group 4 - The refractive surgery market is expected to see a dual impact on performance and valuation due to technological upgrades and the release of pent-up demand [1][41] - The average age of patients undergoing refractive surgery in China is significantly lower than in Europe, indicating a different demographic focus and potential for market expansion [37][38] - The introduction of new materials like EVO+ICL (V5) and Longjing PR is expected to enhance visual quality and safety for patients, further driving market growth [21][27]